Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC [Yahoo! Finance]
Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC
Johnson & Johnson (NYSE:JNJ) had its "buy" rating reaffirmed by analysts at Guggenheim.
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson and Sanofi [Yahoo! Finance]
Johnson & Johnson (JNJ): A Bull Case Theory [Yahoo! Finance]